Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2002-08-17
2008-10-07
Saunders, David A. (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300, C530S388250, C435S007100
Reexamination Certificate
active
07432356
ABSTRACT:
The invention relates to inhibitors that bind to C5 and C5a, but which do not prevent the activation of C5 and do not prevent formation of or inhibit the activity of C5b. One example of such an inhibitor molecule is the monoclonal antibody designated MAb137-26, which binds to a shared epitope of human C5 and C5a. These inhibitors may be used to inhibit the activity of C5a in treating diseases and conditions mediated by excessive or uncontrolled production of C5a. The inhibitor molecules are also useful for diagnostic detection of the presence/absence or amount of C5 or C5a.
REFERENCES:
patent: 5256766 (1993-10-01), Coughlin
patent: WO 01/015731 (2001-03-01), None
Amsterdam, EA et al. Am. J. Physiol.-Heart and Circ. Physiol. [1995] 268:H448-H457.
Güssow, D. (Meth. Enzymology [1991] 203:99-117.
Johnson, RJ et al. J. Immunol. [1997] 138(11):3856-3862.
Ames, RS et al. J. Immunol. [1994] 152:4572-4581.
Larrick et al., Infection and Immunity, 55(8):1867-1872 (1987).
Communication of a Notice of Opposition dated Jan. 31, 2008.
Notice of Opposition to a European Patent dated Jan. 22, 2008 with Annex I and II.
Klos, A. et al. (1988) Jul. 22. “Detection of native human complement components C3 and C5 and their primary activation peptides C3a and C5a (anaphylatoxic peptides) by ELISAs with monoclonal antibodies.” in J. Immunol. Methods 111(2): pp. 241-252.
Stevens, J. et al. (1986), “Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates.” J. clin. Invest. 77: pp. 1812-1816.
Oppermann, M. et al. (1991), “A sensitive enzyme immunoassay for the quantitation of human C5a/C5a(desArg) anaphylatoxin using a monoclonal antibody with specificity for a neoepitope.” Complement Inflamm. 8: pp. 13-24.
Mulligan, M. et al. (1986), “Requirement and role of C5a in acute lung inflammatory injury in rats.” J. Clin. Invest. 98(2): pp. 503-512.
Rinder, C. et al. (1995), “Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation.” J. Clin. Invest. 96: pp. 1564-1572.
Kolb, W. et al., (1975), “The membrane attack mechanism of complement. Isolation and subunit composition of the C5b-9 complex.” J. Exp. Med. 1975: 141(4) pp. 724-735.
Makrides, S. (1998), “Therapeutic inhibition of the complement system.” Pharmocol. Revs. 50(1): pp. 59-87.
Datasheet for Abcam antibody [557] ab11876.
Print Out enquiries from Abcam website.
Kola, A. et al. (1996), “Epitope mapping of a C5a neutralizing mAb using a combined approach of phage display, synthetic peptides and site-directed mutagenesis.” Immunotechnology 2: pp. 115-126.
Hartmann, H. et al., (1993), “Insulin-like growth factor II is involved in the proliferation control of medulloblastoma and its cerebellar precursor cells.” J. Immunol. Methods 166: pp. 35-44.
Takeda, J. et al. (1987), “Rapid and simple measurement of human C5a-des-Arg level in plasma or serum using monoclonal antibodies.” J. Immunol. Methods 101: pp. 265-270.
Schultze, M. & Gotze, O. (1996), “A Sensitive ELISA for the Quantitation of Human C5a in Blood Plasma Using a Monoclonal Antibody.” Complement 3: pp. 25-39.
Alberts et al., Molecular Biology of the Cell, (1983), “How Cells are Studied” and “The Immune System.” Garland Publishing: pp. 182-183 and 965-966.
Fung Michael
Lu Meisheng
Sun Cecily R. Y.
Sun William N. C.
Genentech Inc.
Jones Day
Saunders David A.
VanderVegt F. Pierre
LandOfFree
Complement pathway inhibitors binding to C5 and C5a without... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Complement pathway inhibitors binding to C5 and C5a without..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Complement pathway inhibitors binding to C5 and C5a without... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4002796